
- Industry news
Industry news
- Category news
- Reports
- Key trends
- Multimedia
Multimedia
- Journal
- Events
- Suppliers
Suppliers
- Home
- Industry news
Industry news
- Category news
- Reports
- Key trends
- Multimedia
Multimedia
- Events
- Suppliers
Suppliers
Naturex Granted Fraxinus-Based Patent to Combat Metabolic Syndrome By Improving Blood Sugar Regulation
Naturex announces the approval of U.S. Patent Number: 8,293,292 “Extract of Fraxinus Excelsior seeds and therapeutic applications thereof”.
28 Nov 2012 --- Naturex has developed FraxiPure, an innovative extract of Fraxinus with scientifically-documented properties supporting its use to fight the metabolic syndrome. Metabolic syndrome is a combination of medical disorders that increase the risk of developing cardiovascular diseases and diabetes. According to the World Health Organization, 347 million people worldwide have diabetes. It also predicts that deaths associated with diabetes will increase by two thirds between 2008 and 2030. In the US, 7% of the population is affected by diabetes and it cost the United States an estimated $132 billion in 2002 in medical expenditures.
See more of our coverage in
your Google search results
Upcoming webinars

The future of infant nutrition: From science to success
Valio

From tiny guts to big impact: the powerful potential of probiotics in children’s health
Novonesis

Inside GLP-1 lives: real consumer insights to inspire innovation
FrieslandCampina Ingredients










